ReviewFundamental research2026
Shedding light on the role of extracellular vesicles in renal fibrosis.
Review in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Urinary Extracellular Vesicles Biomarkers in CKD: Clinical Laboratory Translation.Diagnostics (Basel, Switzerland) · 2026Review
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
- Beyond preclinical promise: can mesenchymal stromal cell-derived extracellular vesicles reliably target tubular epithelial cells?Extracellular vesicles and circulating nucleic acids · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal fibrosis is the final common pathway of chronic kidney disease (CKD); thus, preventing the fibrotic process is essential to retarding CKD progression. Extracellular vesicles (EVs) are cell-derived membranous particles comprising exosomes and microvesicles. They carry unique biomolecular cargo from donor to recipient cells and are recognized as a novel mechanism for intercellular communication. There is evidence that EV-mediated cellular crosstalk across the glomerular and tubulointerstitial regions potently participates in the pathogenesis of renal fibrosis. Moreover, due to their outstanding stability and delivery capacity in the body, EVs also show tremendous promise in the diagnosis and treatment of kidney diseases, ushering in a new era of precision theranostics. In this review, we discuss the pathological functions of EVs and highlight the applications of EVs as biomarkers, standalone therapeutics, and novel drug delivery systems for renal fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.